Member Info for Hulver

Other thoughts on factors which may affect possibilities for HG-CT-1 (if it shows efficacy):

- Vlad's desire to see HG-CT-1 right through to a guaranteed completion (I think that is very high, and not to be underestimated). The way things are - if someone wants to be treated with HG-CT-1 they have to use Hemo, Vlad has control of its manufacturing and supply. Potentially HG-CT-1 is better than anything else out there (current triplet therapy mentioned in earlier post) - demand could be high - is there time to get it to the point of being an income stream for Hemo, if results are good does it take that long?

- perhaps whether he thinks HG-CT-1, after initial trial results, is a complete solution to AML or just a stepping stone on the way towards that goal (in which case maybe he would look to a partnership, with CDX included)

- what Vlad, thinks he is sitting on with CBR, and his likelihood of achieving something great for mankind through it (with a Nobel carrot). Perhaps we are waiting on the approval of the CBR patent - for funding to be released for that.

- I cannot see Vlad wanting to work for someone else so unless he is seeking to retire (which i very much doubt) then I cannot see someone buying the company (though I expect there could be a next project to solve, gnawing away at him - and maybe there will be a time to move on to that and let Hemo move on).

In summary, I suspect he will seek to keep control of what he has got for as long as possible still yet.

Blast, this is Nicholas Short (MDA's principal investigator on the HG-CT-1 trial) discussing the analysis and limitations of current triplet therapy treatment.

https://www.vjhemonc.com/video/jjdposxlstq-long-term-survival-and-relapse-patterns-in-flt3-mutated-aml-treated-with-frontline-triplet-therapy/

The triplet therapy combines a hypomethylating agent, venetoclax and then a FLT3 inhibitor. The FLT3 inhibitor improves the length of survival; but where relapses occur it is the continued presence of FLT3 at the time of relapse that results in a rapid decline. Best to read through the narrative, but my reading is that using the FLT3 inhibitor increased 3yr survival to 45% (for ITD mutation) and 76% (for TDK mutation); whereas without the FLT3 inhibitor 2yr survival was just 20% (for ITD) and 40% (for TDK). Bear in mind that with just blood transfusions (no chemo) survival rate may be still 1 - 2 years.

HG-CT-1 is aimed at eliminating the FLT3.

I note that within the first inclusion criteria (there are several) for HG-CT-1 clinical trial protocol are patients with refractory AML (i.e. has not responded to treatment) to a treatment involving a hypomethylating agent and venetoclax. There are other specific inclusion criteria too, and maybe they align with other ongoing trials or current treatments.

I like the reference to 'self-selected team of scientists' - suggests there's a 'belonging' being created for the long term.

I also wondered in the past whether Vlad first come across Haugbro when Haugbro was an intern at Weill Corneill, I think there was a small overlap of time when they were both there.

I see that there was also a great video update as well today: several days in non news is good news: https://www.proactiveinvestors.co.uk/companies/news/1067033/hemogenyx-pharmaceuticals-marks-major-milestone-with-first-patient-dosing.html

"everything is good" - and significant acceleration expected, moving towards 14 days between treatment of patients - and from what he said last summer and again later in the year, there is seemingly no shortage of patients needing this treatment.

Saint/MrsI - thanks for correcting my misinterpretation of the dosing escalation.

That makes a lot of sense - good job I wasn't in charge of administering the treatment.

I am also thinking that if the efficacy is proven sufficient/achieved at the lower doses they possibly won't continue to increase the dose.

Continuations below:

"✅ Capacity to produce HG-CT-1 CAR-T therapy for up to four patients per month

As we continue to expand our capabilities, we look forward to accelerating our clinical study and are already laying the groundwork for the next phase of HG-CT-1 development. Exciting advancements are on the horizon!

🙏 A special thank you to our self-selected team of brilliant scientists and employees, whose dedication and expertise make miracles happen—for the benefit of patients and investors alike. Without these extraordinary members of the Hemogenyx Pharmaceuticals team, none of this would be possible"

VMS Linkedin post this evening:

"🚀 Scaling Innovation: Our Manufacturing Capacity at Hemogenyx Pharmaceuticals

At Hemogenyx Pharmaceuticals, we are committed to pioneering cutting-edge cell and gene therapies. Our state-of-the-art, custom-built facility is designed to meet GMP standards, ensuring high-quality manufacturing of advanced therapeutics.

🔬 Facility Highlights:

✅ Two ISO7-certified clean rooms for cell therapy production

✅ GLP-compliant drug product release testing room for rigorous quality control

✅ Established Quality System to ensure compliance, consistency, and safety

✅ Scalable manufacturing process with a streamlined

Re: Patient 2

If the dose that Patient 1 received is found to be safe then the dosage is escalated and Patient 2 will receive double the dose.

If the dose that Patient 1 received is found not to be safe then the dosage is de-escalated and Patient 2 will receive half the original dose.

OrhyB, isn't that what happened today, perhaps?

Great.

So this is our man on the front line at MD Anderson, Nicholas Short, talking about findings from recent AML trials at ASH in December.

https://www.vjhemonc.com/video/jjdposxlstq-long-term-survival-and-relapse-patterns-in-flt3-mutated-aml-treated-with-frontline-triplet-therapy/

Difficult to follow with the complexity of the subject, but I think the gist of his findings from the triplet combination trial (of existing drugs) are that the use of FLT3 inhibitors in combination with the other two drugs increased survival times for patients, and that those that relapsed with FLT3 still present had worse outcomes.

Hemo's HG-CT-1 is specifically targeting the FLT3 ligand {to eliminate the FLT3 (CD135)?}; so hopefully, if it proves to be safe and effective it may be just the answer that he has been searching for, and perhaps why MD Anderson were keen to be involved in the trial.

I am thinking that relatively quickly (if they haven't done so already) they can start the identification, selection, assay testing and recruiting of Patient 2 now (or as soon as the initial high risk days for Patient 1 are concluded); rather than wait until 28 days before starting that process. You would think some of that work could be done in advance to minimise the time between the results of Patient 1 and treatment of Patient 2, but would welcome any expert view on that.

Can anyone explain what all the matched trades going through today are?

One ordinary execution, matched by one automated execution. This has happened on a few occasions previously too.

24-Feb-25 12:39:16 350.00 158 Sell* 350.00 361.00 553.00 A

24-Feb-25 12:39:03 350.25 158 Sell* 350.00 361.00 553.40 O

Today's lack of a spike v last February seems to indicate the level of collusion that there was with shorters for the spike and sell off on IND approval in February 2024. Are there still short positions open from November/December 2024 following the consolidation announcement?

So the money was already paid over (I am thinking with docs already signed by the lenders)?

Presumably the CLN's were executed today by the company (based on announcement today, as soon as complete).

I am thinking that might have been dependent on a certain stage in the process being reached (e.g. injection ready), or maybe it was just when all the money was in - but if you were lending wouldn't you want some sort of guarantee that things were going to proceed.

So might we be really close to that next RNS?

Let the fountain flow.

Tuan (16.28) to JHFH: 'The fact none of all your predictions come true. Come on show the forum what you said come true.'

JHFH (18.04): 'it should be obvious who sold or shorted today. they can neither buy or close until tomorrow so expect them to remain active tonight'

What entertainment!

I wonder,

is that complete clinical development - as far as they intend to take it (perhaps Phase I); or

complete clinical development (Phase 3) - new drug approval.

Big difference in the amount needed but would be amazing to have the funding sorted, either way.

Micky,

If we do, buy some more.

Well that's certainly kickstarted this board back to life today.

Hopefully, it's now the turn of HG-CT-1 to do the same for our patients.

I'd love to know whether our most experienced financier with a seat on the board was involved in securing this funding - it doesn't sound like it was his idea, so should he now be replaced by JHFH?

If that works out for us - well done sir!

I saw what Prevail did to Briacell recently after announcing positive trial results and share price increased, the next day they raised at a level below what the SP prior to the announcement (exactly what Hemo did last February time).

Thanks for confirming JHFH. Badly worded RNS.

"Subscribers will also receive a one-for-one warrant, exercisable at a price of £4.00 per share for each share held upon the CLN conversion date (the "Warrants")."

Reading that sentence carefully does anyone else interpret it that existing shareholders who have contributed to this CLN are effectively getting a warrant for every share that they already hold (and those they buy between now and 8th March), not just the shares per the CLNs they are being issued?

We do not know how many shares these existing shareholders already hold but this interpretation would mean that certain existing shareholders have been given priority to double their shareholding at a price of £4 per share (i.e. 1p per share in old money). I doubt that some of them could double their holding at that price on the open market!

The warrants only help Hemo's future cashflow if the price increases above £4, so maybe they do expect it to now. But it seems to be a disguised dilution of the non-privileged shareholders. Isn't there a duty under stock exchange regulations to treat all shareholders fairly; and what happened to PR 's statement to the effect that 'we aren't near the point where we need to issue shares at 1p'! That's Hemo's governance, I'm afraid.